Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a growth of 13.66% [2] - The net cash flow from operating activities was 714 million CNY, an increase of 35.39% [2] - The weighted average return on equity was 4.86%, up by 0.68 percentage points year-on-year [2] - The company held cash and cash equivalents of 11.062 billion CNY, with total assets amounting to 54.253 billion CNY [2] R&D Advantages - Strong R&D capabilities with a rich reserve of leading talents, established a joint research center with Peking University [3][4] - Integrated R&D resources across multiple cities, enhancing collaboration with top research institutions [4] - Proactive strategic layout in nuclear medicine, focusing on unmet clinical needs in oncology and immunology [4] - Financial strength to support long-term R&D investments in nuclear medicine [4] Traditional Chinese Medicine (TCM) Supply Chain Development - The company is taking the lead in the TCM supply chain in Yunnan, focusing on seed industry, planting, processing, marketing, and branding [5][6] - Established a specialized company for TCM seed industry, with 4,593 acres of GAP varieties reported in 2024 [6] - Significant growth in production, with a 180% increase in fresh processing and 182% in food and health products [6] - Launched the 'Smart Cloud Medicine' platform, facilitating over 100 million CNY in transactions [6] - Participated in the revision of standards for TCM in the 2025 edition of the Chinese Pharmacopoeia [6] Pharmaceutical Business Growth - The pharmaceutical division focused on comprehensive pain management, enhancing brand recognition in the field [7][8] - Continued clinical research on core products, expanding applications in various medical scenarios [8] - Successful marketing initiatives aimed at younger demographics, leading to increased sales [8] - Established efficient online business processes to enhance operational effectiveness [8]

Group 1: Financial Performance - In Q1 2025, the company achieved a revenue of 10.841 billion CNY, a year-on-year increase of 0.62% [2] - The net profit attributable to shareholders was 1.935 billion CNY, up 13.67% year-on-year [2] - The basic earnings per share reached 1.08 CNY, reflecting a 13.66% increase compared to the previous year [2] - The net cash flow from operating activities was 714 million CNY, showing a significant growth of 35.39% [2] - The weighted average return on equity was 4.86%, an increase of 0.68 percentage points year-on-year [2] - The company had a cash balance of 11.062 billion CNY and total assets of 54.253 billion CNY [2] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment focused on pain management, enhancing brand recognition and product ecosystem [4] - Clinical research in areas such as diabetic foot and skeletal pain showed steady progress, expanding product application scenarios [4] - Successful marketing initiatives, including the 'Walk and Play' campaign, contributed to brand youthfulness and increased product penetration [4] - The company established an efficient operational system to enhance production and marketing effectiveness [4] Group 3: Traditional Chinese Medicine (TCM) Supply Chain Development - The company is committed to leading the TCM supply chain in Yunnan, focusing on seed industry, cultivation, processing, and branding [6] - A new company was established for TCM seed industry, providing control over genetic resources [6] - The processing platform saw a production increase of 180% for medicinal materials and 182% for health products [6] - The 'Smart Cloud Medicine' platform was launched, facilitating transactions exceeding 100 million CNY [6] - The company participated in the revision of standards for TCM products, leading in the development of processing standards [6] Group 4: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with positive stability and safety results reported [8] - The company’s subsidiary received approval for clinical trials of INR102, an innovative radioactive treatment for prostate cancer [8]

Financial Performance - In 2024, the company achieved operating revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - Net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - Non-recurring net profit attributable to shareholders was 4.523 billion CNY, a 20.18% increase from 3.764 billion CNY [2] - Operating cash flow net amount was 4.297 billion CNY, growing by 22.68% [3] - The weighted average return on net assets was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share rose to 2.66 CNY, a 16.16% increase [3] Business Structure and Efficiency - Industrial revenue accounted for 36.14% of total operating revenue, with an industrial revenue growth rate of 5.30% [3] - Industrial gross margin improved to 65.93%, up 1.69 percentage points [3] - Sales expenses decreased by 2.26% year-on-year, while management expenses fell by 1.98% [3] Pharmaceutical Business Performance - The pharmaceutical business group reported main business revenue of 6.924 billion CNY, a year-on-year increase of 11.8% [4] - Sales revenue of Yunnan Baiyao aerosol exceeded 2.1 billion CNY, growing over 26% [4] - Other traditional Chinese medicine products also saw significant growth, with Pudilan's sales nearing 200 million CNY, up over 22% [4] Traditional Chinese Medicine Industry Development - The company is leading the development of Yunnan's traditional Chinese medicine industry, focusing on seed industry, planting, processing, and branding [5][6] - Established Yunnan Baiyao Group Seed Technology Co., Ltd. for seed quality control [6] - The processing platform in Lijiang achieved a production increase of 180% [6] - The "Smart Cloud Medicine" platform launched, facilitating over 100 million CNY in transactions [6] Provincial Pharmaceutical Company Performance - The provincial pharmaceutical company achieved main business revenue of 24.607 billion CNY, a year-on-year increase of 0.48% [7] - Non-drug business sectors like medical devices and special medical foods saw a sales increase of 14% [8] - The OTC sector experienced a sales growth of 18%, while new specialty drug pharmacies grew by 29% [8]